Safer CARS - PubMed (original) (raw)

Editorial

Safer CARS

Helen E Heslop. Mol Ther. 2010 Apr.

No abstract available

PubMed Disclaimer

Comment in

• Is it safer CARs that we need, or safer rules of the road?
  Junghans RP. Junghans RP. Mol Ther. 2010 Oct;18(10):1742-3. doi: 10.1038/mt.2010.162. Mol Ther. 2010. PMID: 20885432 Free PMC article. No abstract available.

Comment on

• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
  Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Morgan RA, et al. Mol Ther. 2010 Apr;18(4):843-51. doi: 10.1038/mt.2010.24. Epub 2010 Feb 23. Mol Ther. 2010. PMID: 20179677 Free PMC article.
• Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
  Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Brentjens R, et al. Mol Ther. 2010 Apr;18(4):666-8. doi: 10.1038/mt.2010.31. Mol Ther. 2010. PMID: 20357779 Free PMC article. No abstract available.

Similar articles

• Is it safer CARs that we need, or safer rules of the road?
  Junghans RP. Junghans RP. Mol Ther. 2010 Oct;18(10):1742-3. doi: 10.1038/mt.2010.162. Mol Ther. 2010. PMID: 20885432 Free PMC article. No abstract available.
• The promise and potential pitfalls of chimeric antigen receptors.
  Sadelain M, Brentjens R, Rivière I. Sadelain M, et al. Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25. Curr Opin Immunol. 2009. PMID: 19327974 Free PMC article. Review.
• Armed T cells with CAR for cancer immunotherapy.
  Wei YQ. Wei YQ. Sci China Life Sci. 2016 Apr;59(4):331-2. doi: 10.1007/s11427-016-5047-0. Epub 2016 Apr 15. Sci China Life Sci. 2016. PMID: 27080712 No abstract available.
• CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.
  Bridgeman JS, Ladell K, Sheard VE, Miners K, Hawkins RE, Price DA, Gilham DE. Bridgeman JS, et al. Clin Exp Immunol. 2014 Feb;175(2):258-67. doi: 10.1111/cei.12216. Clin Exp Immunol. 2014. PMID: 24116999 Free PMC article.
• Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.
  Kenderian SS, Porter DL, Gill S. Kenderian SS, et al. Biol Blood Marrow Transplant. 2017 Feb;23(2):235-246. doi: 10.1016/j.bbmt.2016.09.002. Epub 2016 Sep 13. Biol Blood Marrow Transplant. 2017. PMID: 27638367 Free PMC article. Review.

Cited by

• ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.
  Hong Y, Walling BL, Kim HR, Serratelli WS, Lozada JR, Sailer CJ, Amitrano AM, Lim K, Mongre RK, Kim KD, Capece T, Lomakina EB, Reilly NS, Vo K, Gerber SA, Fan TC, Yu AL, Oakes PW, Waugh RE, Jun CD, Reagan PM, Kim M. Hong Y, et al. Nat Immunol. 2023 Jun;24(6):1007-1019. doi: 10.1038/s41590-023-01498-x. Epub 2023 Apr 17. Nat Immunol. 2023. PMID: 37069398 Free PMC article.
• CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens.
  Maher J, Davies DM. Maher J, et al. Biology (Basel). 2023 Feb 10;12(2):287. doi: 10.3390/biology12020287. Biology (Basel). 2023. PMID: 36829563 Free PMC article. Review.
• Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.
  Billingsley MM, Singh N, Ravikumar P, Zhang R, June CH, Mitchell MJ. Billingsley MM, et al. Nano Lett. 2020 Mar 11;20(3):1578-1589. doi: 10.1021/acs.nanolett.9b04246. Epub 2020 Feb 5. Nano Lett. 2020. PMID: 31951421 Free PMC article.
• Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
  Zhang Z, Jiang J, Wu X, Zhang M, Luo D, Zhang R, Li S, He Y, Bian H, Chen Z. Zhang Z, et al. Front Med. 2019 Feb;13(1):57-68. doi: 10.1007/s11684-019-0683-y. Epub 2019 Feb 5. Front Med. 2019. PMID: 30721445
• Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.
  Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, Giorda E, Scarsella M, Petrini S, Pagliara D, Locatelli F, De Angelis B, Caruana I. Quintarelli C, et al. Oncoimmunology. 2018 Mar 15;7(6):e1433518. doi: 10.1080/2162402X.2018.1433518. eCollection 2018. Oncoimmunology. 2018. PMID: 29872565 Free PMC article.

References

1. 1. Sadelain M, Riviere I., and , Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35–45. - PubMed
2. 1. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261–2271. - PMC - PubMed
3. 1. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106–6115. - PMC - PubMed
4. 1. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24:e20–e22. - PubMed
5. 1. Maher J, Brentjens RJ, Gunset G, Riviere I., and , Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 2002;20:70–75. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

• P01 CA094237/CA/NCI NIH HHS/United States
• P01 CA094237-09/CA/NCI NIH HHS/United States
• P50 CA126752/CA/NCI NIH HHS/United States
• P50 CA126752-04/CA/NCI NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations